company background image
OYST

Oyster Point Pharma NasdaqGS:OYST Stock Report

Last Price

US$5.62

Market Cap

US$150.8m

7D

-15.6%

1Y

-53.0%

Updated

02 Oct, 2022

Data

Company Financials +
OYST fundamental analysis
Snowflake Score
Valuation5/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

OYST Stock Overview

Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States.

Oyster Point Pharma Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Oyster Point Pharma
Historical stock prices
Current Share PriceUS$5.62
52 Week HighUS$19.98
52 Week LowUS$3.46
Beta1.01
1 Month Change-10.51%
3 Month Change27.15%
1 Year Change-53.01%
3 Year Changen/a
5 Year Changen/a
Change since IPO-70.08%

Recent News & Updates

Aug 17

Oyster Point's nasal spray to be covered by largest Medicare pharmacy benefit manager

Oyster Point Pharma (NASDAQ:OYST) on Wednesday said its nasal spray Tyrvaya for the treatment of dry eye disease would now be covered by the largest Medicare pharmacy benefit manager (PBM) in the U.S. OYST did not name the PBM in its statement. Tyrvaya would be added by the PBM on its Medicare part D formularies, effective Sept. 1, OYST said. "In the United States, almost half of the total dry eye disease prescriptions are covered by Medicare...," OYST CEO Jeffrey Nau said. OYST in its Q2 earning report last week said Tyrvaya brought in net product revenue of $4.7M, and that there were about 30K Tyrvaya prescriptions filled during the quarter.

Aug 14
Oyster Point Pharma, Inc. (NASDAQ:OYST) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Oyster Point Pharma, Inc. (NASDAQ:OYST) Analysts Are Cutting Their Estimates: Here's What You Need To Know

There's been a notable change in appetite for Oyster Point Pharma, Inc. ( NASDAQ:OYST ) shares in the week since its...

Shareholder Returns

OYSTUS BiotechsUS Market
7D-15.6%0.4%-2.5%
1Y-53.0%-25.6%-23.2%

Return vs Industry: OYST underperformed the US Biotechs industry which returned -25.6% over the past year.

Return vs Market: OYST underperformed the US Market which returned -23.2% over the past year.

Price Volatility

Is OYST's price volatile compared to industry and market?
OYST volatility
OYST Average Weekly Movement13.1%
Biotechs Industry Average Movement11.1%
Market Average Movement6.8%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: OYST is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: OYST's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2015303Jeff Nauhttps://www.oysterpointrx.com

Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company’s product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy.

Oyster Point Pharma Fundamentals Summary

How do Oyster Point Pharma's earnings and revenue compare to its market cap?
OYST fundamental statistics
Market CapUS$150.79m
Earnings (TTM)-US$157.57m
Revenue (TTM)US$31.94m

4.7x

P/S Ratio

-1.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
OYST income statement (TTM)
RevenueUS$31.94m
Cost of RevenueUS$3.17m
Gross ProfitUS$28.77m
Other ExpensesUS$186.33m
Earnings-US$157.57m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-5.87
Gross Margin90.07%
Net Profit Margin-493.39%
Debt/Equity Ratio848.6%

How did OYST perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is OYST undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for OYST?

Other financial metrics that can be useful for relative valuation.

OYST key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue4.4x
Enterprise Value/EBITDA-1x
PEG Ration/a

Price to Sales Ratio vs Peers

How does OYST's PS Ratio compare to its peers?

OYST PS Ratio vs Peers
The above table shows the PS ratio for OYST vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average9.5x
MREO Mereo BioPharma Group
2.3x43.9%US$93.6m
ARMP Armata Pharmaceuticals
28.5x50.2%US$152.5m
URGN UroGen Pharma
3.3x38.2%US$189.2m
ADCT ADC Therapeutics
4.1x30.0%US$385.3m
OYST Oyster Point Pharma
4.7x51.2%US$150.8m

Price-To-Sales vs Peers: OYST is good value based on its Price-To-Sales Ratio (4.7x) compared to the peer average (9.5x).


Price to Earnings Ratio vs Industry

How does OYST's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Sales vs Industry: OYST is good value based on its Price-To-Sales Ratio (4.7x) compared to the US Biotechs industry average (13.2x)


Price to Sales Ratio vs Fair Ratio

What is OYST's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

OYST PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio4.7x
Fair PS Ratio18.2x

Price-To-Sales vs Fair Ratio: OYST is good value based on its Price-To-Sales Ratio (4.7x) compared to the estimated Fair Price-To-Sales Ratio (18.2x).


Share Price vs Fair Value

What is the Fair Price of OYST when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: OYST ($5.62) is trading below our estimate of fair value ($263.78)

Significantly Below Fair Value: OYST is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Future Growth

How is Oyster Point Pharma forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


62.2%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: OYST is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: OYST is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: OYST is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: OYST's revenue (51.2% per year) is forecast to grow faster than the US market (7.7% per year).

High Growth Revenue: OYST's revenue (51.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if OYST's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Oyster Point Pharma performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-45.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: OYST is currently unprofitable.

Growing Profit Margin: OYST is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: OYST is unprofitable, and losses have increased over the past 5 years at a rate of 45.3% per year.

Accelerating Growth: Unable to compare OYST's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OYST is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).


Return on Equity

High ROE: OYST has a negative Return on Equity (-1462.35%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Oyster Point Pharma's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: OYST's short term assets ($132.7M) exceed its short term liabilities ($31.1M).

Long Term Liabilities: OYST's short term assets ($132.7M) exceed its long term liabilities ($102.0M).


Debt to Equity History and Analysis

Debt Level: OYST has more cash than its total debt.

Reducing Debt: Insufficient data to determine if OYST's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: OYST has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: OYST has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 48.5% each year.


Discover healthy companies

Dividend

What is Oyster Point Pharma current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Oyster Point Pharma Dividend Yield vs Market
How does Oyster Point Pharma dividend yield compare to the market?
SegmentDividend Yield
Company (Oyster Point Pharma)n/a
Market Bottom 25% (US)1.7%
Market Top 25% (US)4.7%
Industry Average (Biotechs)2.8%
Analyst forecast in 3 Years (Oyster Point Pharma)n/a

Notable Dividend: Unable to evaluate OYST's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate OYST's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if OYST's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OYST's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as OYST has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Jeff Nau (47 yo)

5yrs

Tenure

US$2,803,339

Compensation

Dr. Jeffrey Nau, also known as Jeff, Ph. D, M. M. S, has been President, Chief Executive Officer and Director at Oyster Point Pharma, Inc since October 2017. Dr. Nau served as Vice President of Clinical an...


CEO Compensation Analysis

Jeff Nau's Compensation vs Oyster Point Pharma Earnings
How has Jeff Nau's remuneration changed compared to Oyster Point Pharma's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a

-US$158m

Mar 31 2022n/an/a

-US$130m

Dec 31 2021US$3mUS$563k

-US$101m

Sep 30 2021n/an/a

-US$81m

Jun 30 2021n/an/a

-US$79m

Mar 31 2021n/an/a

-US$73m

Dec 31 2020US$6mUS$530k

-US$71m

Sep 30 2020n/an/a

-US$68m

Jun 30 2020n/an/a

-US$63m

Mar 31 2020n/an/a

-US$58m

Dec 31 2019US$4mUS$390k

-US$46m

Sep 30 2019n/an/a

-US$30m

Jun 30 2019n/an/a

-US$25m

Mar 31 2019n/an/a

-US$17m

Dec 31 2018US$390kUS$300k

-US$17m

Compensation vs Market: Jeff's total compensation ($USD2.80M) is above average for companies of similar size in the US market ($USD1.69M).

Compensation vs Earnings: Jeff's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: OYST's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

Experienced Board: OYST's board of directors are considered experienced (3.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of OYST?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders365,5481.4%
General Public2,062,6097.7%
Institutions6,638,90024.7%
Hedge Funds8,181,52330.5%
VC/PE Firms9,582,90535.7%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.1%.


Top Shareholders

Top 25 shareholders own 89.24% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
22.08%
New Enterprise Associates, Inc.
5,925,287$33.3m0%1.49%
13.63%
Versant Venture Management, LLC
3,657,618$20.6m0%4.33%
10.32%
Invus Financial Advisors, LLC
2,768,586$15.6m0%8.93%
7.67%
RTW Investments, LP
2,058,504$11.6m0%0.25%
7.05%
Point72 Asset Management, L.P.
1,891,857$10.6m-4.06%0.03%
5.45%
Paradigm Biocapital Advisors LP
1,462,576$8.2m9.69%1.64%
3.87%
KKR & Co. Inc.
1,039,622$5.8m0%0.04%
2.9%
Telemark Asset Management, LLC
777,026$4.4m-1.27%0.74%
2.48%
The Vanguard Group, Inc.
666,715$3.7m-0.14%no data
1.99%
BlackRock, Inc.
533,284$3.0m-51.16%no data
1.9%
Cowen Inc,Private Banking and Investment Banking Investments
509,794$2.9m0%0.34%
1.73%
GW&K Investment Management, LLC
464,383$2.6m2.25%0.03%
1.37%
Kleiner Perkins Caufield & Byers
367,987$2.1m0%0.25%
0.87%
Wellington Management Group LLP
232,267$1.3m-57.1%no data
0.83%
Citadel Advisors LLC
223,465$1.3m111.05%no data
0.79%
Manulife Asset Management
212,087$1.2m-1.53%no data
0.78%
Laurion Capital Management LP
210,200$1.2m0%0.05%
0.52%
Morgan Stanley, Investment Banking and Brokerage Investments
139,109$781.8k32.94%no data
0.5%
Millennium Management LLC
134,638$756.7k0%no data
0.45%
Geode Capital Management, LLC
121,940$685.3k-40.64%no data
0.44%
Mark Murray
118,513$666.0k3.01%no data
0.43%
Strategic Advisers LLC
115,496$649.1k14.04%no data
0.4%
Creative Planning, LLC
106,662$599.4k0%no data
0.39%
HSBC Global Asset Management (UK) Limited
103,510$581.7k0%no data
0.38%
Barclays PLC Private Banking & Investment Banking Investment
103,016$578.9k-1.72%no data

Company Information

Oyster Point Pharma, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Oyster Point Pharma, Inc.
  • Ticker: OYST
  • Exchange: NasdaqGS
  • Founded: 2015
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$150.793m
  • Shares outstanding: 26.83m
  • Website: https://www.oysterpointrx.com

Number of Employees


Location

  • Oyster Point Pharma, Inc.
  • 202 Carnegie Center
  • Suite 109
  • Princeton
  • New Jersey
  • 8540
  • United States


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
OYSTNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDOct 2019

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/10/02 00:00
End of Day Share Price2022/09/30 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.